Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 6/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.38 |
| ▸ | NOS1 | P29475 | 3/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | ARG1 | P05089 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | NOS3 | P29474 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6636963 | 0.82 | TLR8 (0.43) | TLR8TSHRARG1 | |
| SCHEMBL6636184 | 0.80 | TLR8 (0.49) | TLR8TSHRARG1BRD4 | |
| SCHEMBL6639655 | 0.76 | CHRNA7 (0.50) | TLR8 | |
| SCHEMBL6640843 | 0.75 | TLR8 (0.47) | TLR8TSHRARG1 | |
| SCHEMBL6638993 | 0.74 | TLR8 (0.50) | TLR8ARG1CYP3A4 | |
| SCHEMBL6637907 | 0.73 | TLR8 (0.43) | TLR8TSHRCYP11B1CYP11B2ARG1 | |
| SCHEMBL8543898 | 0.71 | TLR8 (0.50) | TLR8ARG1CYP3A4 | |
| SCHEMBL6642392 | 0.71 | TLR8 (0.46) | TLR8TSHRARG1 | |
| SCHEMBL7126841 | 0.70 | CHRNB2 (0.45) | CYP11B1CYP11B2 | |
| SCHEMBL6638666 | 0.69 | TLR8 (0.47) | TLR8ARG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1185521-B1 | SUBSTITUTED 1-AZA-2-IMINO-HETEROCYCLES AND THEIR USE AS ACTIVATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | DAIICHI SUNTORY PHARMA CO LTD (JP) | 2004-10-06 | — | — | EP | claimed |
| US-20030134848-A1 | Substituted 1-aza-2-imino-heterocycles and their use as nicotinic acetylcholin receptors activators | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2003-07-17 | — | — | US | claimed |
| CN-1366521-A | Substituted 1-aza-2-imino heterocycles and their use as nicotinic acetylcholine receptors activators | SUNTORY LTD (JP) | 2002-08-28 | — | — | CN | claimed |
| EP-1185521-A1 | SUBSTITUTED 1-AZA-2-IMINO-HETEROCYCLES AND THEIR USE AS ACTIVATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | SUNTORY LIMITED (JP) | 2002-03-13 | — | — | EP | claimed |
| WO-2001081326-A1 | SUBSTITUTED 1-AZA-2-IMINO-HETEROCYCLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTORS ACTIVATORS | SUNTORY LIMITED (JP) | 2001-11-01 | — | — | WO | claimed |
| EP-1185521-B1 | SUBSTITUTED 1-AZA-2-IMINO-HETEROCYCLES AND THEIR USE AS ACTIVATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | DAIICHI SUNTORY PHARMA CO LTD (JP) | 2004-10-06 | — | — | EP | disclosed |
| US-20030134848-A1 | Substituted 1-aza-2-imino-heterocycles and their use as nicotinic acetylcholin receptors activators | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2003-07-17 | — | — | US | disclosed |
| CN-1366521-A | Substituted 1-aza-2-imino heterocycles and their use as nicotinic acetylcholine receptors activators | SUNTORY LTD (JP) | 2002-08-28 | — | — | CN | disclosed |
| EP-1185521-A1 | SUBSTITUTED 1-AZA-2-IMINO-HETEROCYCLES AND THEIR USE AS ACTIVATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | SUNTORY LIMITED (JP) | 2002-03-13 | — | — | EP | disclosed |
| WO-2001081326-A1 | SUBSTITUTED 1-AZA-2-IMINO-HETEROCYCLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTORS ACTIVATORS | SUNTORY LIMITED (JP) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134848-A1 | Substituted 1-aza-2-imino-heterocycles and their use as nicotinic acetylcholin receptors activators | CHRNA7, CHRNA2, CHRNA1 | TLR8 1132/4885TSHR 532/4885CYP11B1 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.